Nutritional blend to improve lung function in post-COVID-19 patients
EFFECTS OF WHEY PROTEIN SUPPLEMENTATION ON CARDIOPULMONARY, MUSCLE AND IMMUNOHEMATOLOGICAL RESPONSES OF POST-COVID-19 PATIENTS.
PHASE3 · Federal University of São Paulo · NCT06166030
This study tests if a special nutritional blend can help improve lung function and muscle strength in people recovering from moderate COVID-19.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 58 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Federal University of São Paulo (other) |
| Locations | 2 sites (Sao Jose dos Campos, Sao Paulo and 1 other locations) |
| Trial ID | NCT06166030 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a 30-day supplementation with a nutritional blend called ImmuneRecov® on post-COVID-19 patients who have experienced respiratory and muscular impairments. The blend includes ingredients such as whey protein, astaxanthin, creatine, and vitamins aimed at enhancing lung function and muscle strength. The study is a non-controlled open label prospective clinical trial involving 58 post-COVID-19 patients, with evaluations conducted before and after the supplementation period. Participants were selected based on their hospitalization due to moderate COVID-19 severity.
Who should consider this trial
Good fit: Ideal candidates are post-COVID-19 patients who were hospitalized and classified with moderate illness according to WHO criteria.
Not a fit: Patients who have been discharged for more than 14 days or those who have started physical activity or taken dietary supplements will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve respiratory function and muscle strength in patients recovering from COVID-19.
How similar studies have performed: While there have been various studies on post-COVID-19 rehabilitation, the specific approach of using this nutritional blend is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: The inclusion criteria encompassed post-COVID-19 patients with a confirmed COVID-19 diagnosis through a positive RT-PCR test, who also required hospitalization, meeting the criteria for moderate severity classification as defined by the World Health Organization (WHO). In summary, according to the WHO, moderate illness is characterized by individuals who exhibit signs of lower respiratory disease during clinical assessment or imaging and maintain an oxygen saturation level (SpO2) of ≥94% while breathing room air at sea level. Exclusion Criteria: Exclusion criteria included individuals discharged from the hospital for more than 14 days and those who initiated physical activity or began taking any dietary supplements or vitamins.
Where this trial is running
Sao Jose dos Campos, Sao Paulo and 1 other locations
- Laboratory of Pulmonary and Exercise Immunology — Sao Jose dos Campos, Sao Paulo, Brazil (RECRUITING)
- Laboratory of Pulmonary and Exercise Immunology - Federal University of Sao Paulo — São José dos Campos, SP, Brazil (RECRUITING)
Study contacts
- Principal investigator: Rodolfo de Paula Vieira, BSc., MSc., PhD. — Federal University of São Paulo
- Study coordinator: Rodolfo de Paula Vieira, BSc., MSc., PhD.
- Email: rodrelena@yahoo.com.br
- Phone: 55 12 991410615
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Long Covid19, Dietary Supplements, Respiratory Tract Infections, Inflammation, COVID-19, dietary supplementation, inflammation, lung function